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Introduction
 UICC is a membership organization that exists to help 
the global health community accelerate the fight against 
cancer. Founded in 1933 and based in Geneva, UICC’s 
growing membership of over 760 organizations across 
155 countries, features the world’s major cancer societies, 
ministries of health, research institutes and patient groups. 
Together with its members, key partners, the World Health 
Organization, World Economic Forum and others, UICC 
is tackling the growing cancer crisis on a global scale. 
 As part of the official program of the 72nd Annual 
Meeting of the Japanese Cancer Association the Japan 
National Committee for UICC and UICC-Asia Regional 
Office (ARO) organized an international session to discuss 
the topic “What is cost-effectiveness in cancer treatment?” 
Presenters and participants discussed the question of how 
limited medical resources can be best used to support 
life, which is a question that applies to both developing 
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Abstract
 The Japan National Committee for the Union for International Cancer Control (UICC) and UICC-Asia 
Regional Office (ARO) organized an international session as part of the official program of the 72nd Annual 
Meeting of the Japanese Cancer Association to discuss the topic “What is cost-effectiveness in cancer treatment?” 
Healthcare economics are an international concern and a key issue for the UICC. The presenters and participants 
discussed the question of how limited medical resources can be best used to support life, which is a question that 
applies to both developing and industrialized countries, given that cancer treatment is putting medical systems 
under increasing strain. The emergence of advanced yet hugely expensive drugs has prompted discussion on 
methodologies for Health Technology Assessment (HTA) that seek to quantify cost and effect. The session benefited 
from the participation of various stakeholders, including representatives of industry, government and academia 
and three speakers from the Republic of Korea, an Asian country where discussion on HTA methodologies is 
already advanced. In addition, the session was joined by a representative of National Institute for Health and Care 
Excellence (NICE) of the United Kingdom, which has pioneered the concept of cost-effectiveness in a medical 
context. The aim of the session was to advance and deepen understanding of the issue of cost-effectiveness as 
viewed from medical care systems in different regions.
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and industrialized countries, given that cancer treatment 
is putting medical systems under increasing strain. The 
emergence of advanced yet hugely expensive drugs 
has prompted discussion on methodologies for Health 
Technology Assessments (HTA) that seek to quantify cost 
and effect. The session benefited from the participation of 
various stakeholders, including representatives of industry, 
government and academia and three speakers from the 
Republic of Korea, an Asian country where discussion 
on HTA methodologies is already advanced. 
 In addition, the session was joined by a representative 
of National Institute for Health and Care Excellence 
(NICE) of the UK. The aim was to advance and deepen 
understanding of the issue of cost-effectiveness as viewed 
from medical care systems in different regions. The session 
was co-chaired by Hideyuki Akaza, Research Center for 
Advanced Science and Technology, The University of 
Tokyo, Japan, and Jae Kyung Roh, Yonsei Cancer Center, 
Yonsei University Medical School, Republic of Korea.
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Opening Remarks
 Hideyuki Akaza (RCAST) welcomed participants 
to the UICC International Session, entitled “What is 
cost-effectiveness in cancer treatment?” The session was 
being hosted by the UICC Japan Office and UICC-Asia 
Regional Office (ARO) (Akaza, 2013). He began by 
noting the great cost involved in developing new anti-
cancer drugs and the problems this is creating all around 
the world. He explained that the first three presentations 
would present perspectives on cost-effectiveness from 
the government and administrative side, following which 
two presentations would discuss cost-effectiveness from 
an academic perspective. Finally, the issue of cost-
effectiveness would be presented from the viewpoint of 
pharmaceutical companies. Following the presentations 
there would be time for general discussion. Jae Kyung 
Roh (Yonsei University), acting as co-chair with Hideyuki 
Akaza also welcomed participants. 
1. Recent Discussion on Cost-effectiveness at 
the Health Ministry’s Council 
 Hajime Inoue (Ministry of Health, Labour and Welfare 
(MHLW)) noted that in many areas of cancer treatment, 
the introduction of new tracks of drugs completely changes 
the way patients are treated. One of the key factors is 
the fair evaluation of new medicine. He reported on the 
recent considerations with regard to cost-effectiveness at 
the MHLW ministry council. 
 In Japan the prices of all prescription medicines are 
priced at the Central Social Insurance Medical Council 
(“Chuikyo”). All cancer drugs are promptly covered, 
priced and made accessible to all. Pricing is based on 
“added value” compared to existing analogous drugs, or 
on “cost accounting” methods if no analogous drugs exist. 
Price adjustment is based on the foreign price of the drugs 
in question. Until recently Hajime Inoue had served as the 
secretary of the Chuikyo council meeting. The pricing 
of new medicine is one of the highest concerns for all 
stakeholders involved. Many people are not completely 
satisfied with the current pricing mechanism, which is 
considered to be overly vague and does not reflect the 
current situation with medical innovation. In February 
2012 Chuikyo made a resolution to request the MHLW 
minister to examine the feasibility of evaluating the cost 
effectiveness of new technologies, including new cancer 
drugs.
 Since May 2012 the Chuikyo Subcommittee on 
Cost-Effectiveness Analysis has met on 13 occasions 
and a provisional draft report was issued in September 
2013. Points of issue include cost, effectiveness and 
application, although subcommittee members have yet to 
reach a decision on how to define cost, how to measure 
effectiveness, and how to apply cost-effectiveness analysis 
into the pricing system. There are two major concerns that 
underlie the technical discussions in this subcommittee, 
namely how does cost-effectiveness affect price of and 
access to new drugs.
 With regard to pricing, the concern is that if cost-
effectiveness is another word for price containment, there 
are precedents in other countries where new drugs have 
been contained. On the other hand, cost-effectiveness 
could be viewed as simply differentiating real innovation 
from mediocre efforts, and pricing accordingly.
With regard to access, there are concerns that cost-
effectiveness analysis could hinder access if coverage 
is restricted, as has been the case in other countries. On 
the other hand, it could be viewed that cost-effectiveness 
analysis is simply a method to redistribute finite resources 
for more effective use.
 In the ongoing discussions at the Chuikyo ministry 
council further considerations will be required in order to 
reach convergence. It is necessary to devise an objective, 
reliable index (or combination of indices) to measure 
effectiveness in a Japanese context. Quality Adjusted 
Life Years (QALY) is one method of measuring cost-
effectiveness, but it is insufficient on its own. Another 
concern of the MHLW ministry council is to identify 
real innovation and price accordingly, thereby rewarding 
innovation and not containing it. Another issue is to 
discuss the ways in restriction on drugs could be accepted 
in the case of “less-effective” use.
2. Cost Effectiveness of Cancer Treatment 
in Korea 
 Eun-Cheol Park (Yonsei University) noted that his 
presentation would include three parts: the burden of 
cancer in Korea, cost-effectiveness analysis (CEA) for 
cancers and conclusions. Annual cancer incidence and 
mortality rates are increasing rapidly in Korea, with the 
cumulative risk of cancer standing at 37.6% for males 
and 33.3% for females (as of 2010). Cancer accounts for 
27.8% of all deaths in Korea (as of 2012). The economic 
burden of cancer has been estimated at US$24.1 billion. 
Disability adjusted life years (DALY) are expected to 
continue to increase for almost all cancers.
 With regard to CEA, the first question to ask is if 
prevention better than cure. If incremental effectiveness 
exceeds the incremental cost, then it can be considered 
that prevention is better than cure. Cost-effectiveness 
can be measured in terms of life years saved, QALY 
and direct/indirect benefits. In monetary terms it is 
possible to consider a human capital approach and also 
a willingness to pay. The dimensions of cancer control 
include prevention, early detection, diagnosis and 
treatment, and palliative care. Contributing factors such 
as smoking, alcohol consumption, infection and obesity all 
can be controlled to reduce the likelihood of contracting 
cancer. In terms of CEA results, one study showed that 
the eradication of helicobacter pylori in gastric cancer 
survivors after endoscopic resection of early gastric cancer 
reduced overall costs by US$814 and resulted in LYS of 
0.05 years. 
 Early detection is also very important and in Korea 
the National Cancer Screening Program (NCSP) has 
been in operation since 1999. Screening for various types 
of cancer, including stomach, liver, colorectal, breast 
and cervical cancers, are implemented regularly for the 
entire population in certain age groups. However, CEA in 
Korea has shown that for some cancers, including breast 
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cancer, treatment is cost-effective in Western countries, 
but not cost-effective in Asian countries. There is also 
divergence in the quality of care provided, depending on 
the geographic location of the hospital providing care. 
In Korea efforts are being made to engage in primary 
prevention efforts for the most prevalent forms of cancer, 
including stomach, liver, colorectal and lung cancers. 
Efforts include anti-smoking campaigns and information 
about how to reduce salt intake. Early detection is another 
area that is being increasingly focused on. Palliative care 
efforts include the expansion of hospices and the creation 
of models for acute palliative care.
More evidence is required concerning methods for 
reducing the burden of cancer, including effectiveness 
and cost-effectiveness evidence.   
3. Current Decision-making of Natl Health 
Insurance on Anti-cancer Drugs in Korea
 Sukyeong Kim (Health Insurance Review and 
Assessment Service (HIRA)) began by explaining 
about the introduction of a positive list system in Korea. 
She noted that a high proportion of pharmaceutical 
expenditure has always been a big burden in national 
health expenditure in Korea, at a higher than average level 
in comparison to other Organization for Economic Co-
operation and Development (OECD) countries (24-25% 
vs. 17-18%). In terms of the National Health Insurance 
(NHI) pharmaceutical expenditure, the annual growth rate 
was 14.6% between 2001 and 2005, with pharmaceuticals 
accounting for 29% of all NHI spending in 2005. The 
increases can be explained by an aging population and 
an increase in chronic diseases and the early adoption of 
new drugs and wide NHI coverage of pharmaceuticals. 
The government of Korea announced a Pharmaceutical 
Expenditure Reconciliation Plan in May 2006, following 
by the adoption of the positive list system in December 
2006. 
 Under the positive list system selective reimbursement 
for new drugs is based on cost effectiveness in addition 
to clinical usefulness. Furthermore, decisions on 
reimbursement and decisions on pricing of new drugs 
have been split into two. The reimbursement assessment 
is implemented by HIRA, while price negotiation is 
undertaken between the National Health Insurance Service 
(NHIS) and the manufacturer. The system is subject to 
review, with drugs being delisted if they have not been 
produced or subject to a claim for two years or more, and 
reevaluation also being implemented on reimbursement 
status and price. 
 Before the positive list system was introduced 
almost all drugs were covered by the NHI system. 
Following the introduction, only drugs with clinical and 
economic value are covered. A Drug Benefit Assessment 
Committee (DBAC) comprising 21 specialists from 
various stakeholders, including companies, consumers 
and government agencies assess drug appropriateness and 
recommend reimbursement. There is also an Anticancer 
Drugs Review Committee under the DBAC that advises 
and controls the off-label use of anti-cancer drugs. The 
DBAC considers “essential drugs” to be those that fulfill 
the following criteria: No alternative treatments and drugs; 
use for severe, life-threatening diseases; use for a minority 
of patients who have rare diseases etc.; and drugs that are 
proven to provide clinically meaningful improvement 
for patients. NHIS negotiates drug price and its expected 
volume with the company after a decision has been made 
by the DBAC.
 In terms of the evaluation of the positive list system, 
the average recommendation rate from 2009 to 2012 was 
73%. A total of 92% of recommended drugs satisfied all 
decision criteria and 59% of rejected drugs demonstrated 
unacceptable cost-effectiveness. Comparisons with cases 
in Australia and Canada have shown that there is no 
evidence to suggest that Korea is more conservative in its 
recommendation procedures than the two abovementioned 
countries, with similar decisions forthcoming from all 
three countries in terms of clinical usefulness, although 
there were differences in cost-effectiveness assessments.
With regard to NHI coverage decisions on anti-cancer 
drugs, the recommendation rate is almost the same as 
common drugs. In comparison with the Common Drug 
Review (CDR) of Canada and NICE UK, recommendation 
rates are similar for anti-cancer drugs. Off-label use of 
anti-cancer drugs is reviewed by an expert committee. 
Government policy in Korea is to expand coverage to 
100% for anti-cancer drugs, although decisions have 
yet to be reached on a number of new drugs, or they 
have already been rejected. Policies will also need to be 
formulated in the future to respond to ultra-high cost drugs 
and rare diseases. A special mechanism also needs to be 
devised that incorporates end of life treatment (including 
a weighting for QALY), utilization monitoring and 
assessment of off-label use of anti-cancer drugs.  
4. NICE Methods to Assess Cost-Effectiveness 
of Cancer Treatments in England
 Jasdeep Hayre (National Institute for Health and Care 
Excellence (NICE)) began with an explanation about 
the background to NICE. The United Kingdom (UK) 
has an entirely taxpayer-funded system with no public 
health insurance scheme and results in fixed budgets with 
scarce resources in the health service. In the 1990s, local 
commissioners and providers at the local level would 
make decisions about what was made available to local 
populations. This system led to a so-called “postcode 
lottery” for patients, where treatment would differ 
depending on geographic location. There was public and 
political dissatisfaction with the availability of treatments. 
NICE was formed in 1999 and is based on four 
principles that underpin all NICE guidance: 1) based 
on the best available evidence, 2) maximize clinical 
and cost effectiveness, 3) developed systematically 
and transparently, and 4) developed with stakeholder 
engagement. From 1 March 2000 to 31 August 2013 NICE 
has looked at over 500 treatments, over 130 of which have 
been for cancer. Over 170 guidelines have been issued, 
over 10 of which have been for cancer. 
 With regard to cost effectiveness issues, NICE’s aim 
is to maximize health benefit given budget constraints. 
What NICE is interested in is comparative or incremental 
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differences between drugs, namely is the extra health gain 
from a certain new drug worth the extra money spent? 
In order to measure the health gain, NICE uses Quality 
Adjusted Life Years (QALY). QALYs combine both 
quantity and health-related quality of life (QoL) into a 
single measure of health gain. The amount of time spent 
in a health state is weighted by the QoL score attached to 
that health state. The benefit of the QALY is that it can 
weigh up the net effect of treatment for patients, including 
survival vs. QoL, long-term QoL for chronic and recurrent 
conditions, and benefits vs. harms. 
 In terms of economic evaluation and decision making, 
NICE uses the incremental cost effectiveness ratio (ICER), 
which gives the cost per one QALY gained. If the ICER 
is above £20,000 to £30,000 per QALY gained, a stronger 
case is needed to recommend the drug. 
 In terms of the appraisal process, under a single 
technology appraisal process a company generally 
submits a new drug for assessment by an external review 
group. The appraisal committee then produces draft 
advice to approve, reject or restrict access to the drug, 
with comments also being received from stakeholders, 
after which guidance is issued. An appeal process is also 
incorporated. There are different processes for all other 
NICE guidance (including guidelines, diagnostics, and 
interventional procedures). However, there are further 
“special circumstances” that also need to be taken into 
consideration. The application of “special circumstances” 
in the appraisal of some products with ICERs above 
£30,000 per QALY has been seen in a number of cancer 
drugs. Several special circumstances have been applied 
in the past, including consideration of “severity,” “end-of-
life,” “stakeholder persuasion,” “significant innovation,” 
“disadvantaged populations” and “children.” (Rawlins et 
al.,, 2010).
 Most relevant to cancer are the “end-of-life” criteria. 
Additional consideration can be given for treatments 
which affect people at the end of their life (usually with 
cancer). End-of-life criteria can be applied if the following 
conditions are met: the treatment is indicated for patients 
with a short life expectancy, normally less than 24 
months, and there is sufficient evidence to indicate that the 
treatment offers an extension to life, normally of at least 
an additional 3 months, compared with current National 
Health Service treatment, and the technology is licensed 
or otherwise indicated, for small patient populations 
normally not exceeding a cumulative total of 7,000 for 
all licensed indications in England. 
 Looking at both economic considerations and special 
circumstances, NICE has approved approximately 
58% cancer drug indications (63% for non-cancer drug 
indications) or optimized 4% of cancer drug indications 
(17% for non-cancer drug indications), which is broadly 
in line with international trends although a little more 
conservative than approval processes in seen in Asia. 
There may be a political and social argument for accepting 
more cancer drugs and the question of whether cancer 
treatments should have a higher ICER threshold (greater 
than £30,000 per QALY) is one that is still being discussed. 
There is no significant academic evidence to show 
that cancer drugs should be given a higher acceptance 
threshold than for other drugs. 
With regard to the Cancer Drugs Fund, this scheme 
was introduced by the Department of Health in April 
2011 to “enable patients to access the cancer drugs their 
doctors think will help them.” Additional government 
funding (£200 million) has been provided to pay for 
drug / indication combinations appraised by NICE and 
not recommended on the basis of cost effectiveness, or 
where the recommendations materially restrict access 
to the treatment to a smaller group of patients than the 
specifications set out in the marketing authorization 
(an ‘optimized’ recommendation), and drug / indication 
combinations on which NICE has not, or not yet, issued 
appraisal guidance. Very recently a further £400 million 
was provided for the fund, which will ensure funding up 
to March 2016. The fund covers around 31 drugs (108 
indications) and in one quarter there were almost 5,000 
prescriptions. The most popular drugs prescribed under 
the fund are bevacizumab and abiraterone. The most 
prescribed indication for bevacizumab using the fund was 
for an indication NICE had rejected. The most prescribed 
indication for abiraterone using the fund was for one which 
had not been appraised by NICE.
 In summary, NICE provides a robust and transparent 
system to assess all treatments, including cancer 
treatments and interventions for a fixed budget system. 
Some special circumstances can be considered. Although 
this system may not be a perfect solution it does approve 
approximately 64% of anti-cancer indications. There 
is some political willingness to go further and perhaps 
give cancer drugs more “weight” or funding, through the 
Cancer Drugs Fund. 
5. Cost-effectiveness Analyses and Cancer 
Treatment in Japan
 Takashi Fukuda (National Institute of Public Health) 
noted that in Japan a public health insurance scheme 
covers the whole population, however, there are about 
3,000 health insurance bodies. People in Japan have 
to join one of the health insurance bodies. In 2010, 
annual medical expenditure was around 37 trillion yen, 
which is approximately 7.8% of gross domestic product 
(GDP). Medical expenditure continues to increase by 
approximately 1 trillion yen each year. One of the reasons 
for the increase in medical expenditure is population 
aging. Elderly people account for approximately 23% 
of the total population. Another significant reason is the 
ongoing advancement of technologies in health care and 
new drugs. Cancer accounts for a large proportion of 
medical expenditure (approximately 3.5 trillion yen in 
2010).
 Even though medical expenditure of cancer is 
increasing, the economic burden to society may be 
decreasing, because of decreased mortality at younger 
ages. However, increased medical expenditure must be 
borne by health care finance. Especially in recent years, 
expensive drugs and treatments have appeared and they 
may cost a great deal of money. The question this presents 
is: should we avoid expensive drugs and treatment because 
of large expenditure? 
Asian Pacific Journal of Cancer Prevention, Vol 15, 2014 7
            DOI:http://dx.doi.org/10.7314/APJCP.2014.15.1.3
Meeting Report - What is Cost-effectiveness in Cancer Treatment?
 The issue of harmonizing advancing technology and 
expenditure is a difficult one to address. It is difficult to 
increase taxation, insurance premiums and patients’ out-
of-pocket payments due to the current economic climate 
in Japan. It would also be difficult to limit the extent of 
insurance coverage, as all prescription drugs are covered 
by the national health insurance scheme. There are also 
questions about whether to implement price or volume 
controls, but this could cause inequality in the system. 
 One example of cost-effectiveness analysis of a 
molecular-targeting drug is adjuvant trastuzumab. After 
2005, several randomized control trials (RCTs) have 
confirmed the usefulness of trastuzumab as adjuvant 
therapy for HER2-positive patients, not only as metastatic 
therapy. However, the costs of one year of treatment are 
approximately 3.2 million yen. Adjuvant trastuzumab 
is “revolutionary” treatment but the costs are not low. 
Although initial costs are high it is highly possible that 
adjuvant trastuzumab treatment may reduce the medical 
costs of recurrence or metastatic breast cancer patients. 
The objective of this study was to evaluate efficiency 
by performing cost-effectiveness analysis of adjuvant 
trastuzumab treatment compared with observation alone. 
Cost-effectiveness analysis was implemented with an 
outcome measure of life-years gained (LYG). Efficacy data 
was based on the 2-year HERA interim analysis in 2007. 
Only direct medical costs were estimated based on the 
Japanese drug tariff and reimbursement schedule in 2004, 
not including indirect costs. It is unknown how long the 
effect of trastuzumab continues. The cost-effectiveness of 
trastuzumab was calculated for three hypothetic scenarios, 
with risk reduction continuing constantly for two years, 
five years, and ten years. The recurrence risk after five 
years was assumed to be half that of the previous five 
years, continuing for the patients’ lifetime by Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) meta-
analysis. The period of trastuzumab efficacy was the most 
influential parameter on the result of cost-effectiveness. 
However, when trastuzumab efficacy continues for more 
than two years, at least, which is a conservative setting 
judging from the joint analysis (NSABP B-31 and NCCTG 
N9831 trials), the ICER is less than JPY 7,500,000 for any 
patient weight class.
 NICE suggests that the ICER threshold should be 
£20,000 to £30,000 (=3,000,000 to 5,000,000 yen) per 
QALY, however, in Japan, 5,000,000 to 6,000,000 yen 
per QALY is often referred to as a benchmark, based on 
a willingness-to-pay (WTP) study.
 In the trastuzumab study, the outcome measure was not 
QALY, but LYG. However, as the therapy mainly prolongs 
progression-free survival, patient QoL during the period 
would be not so bad. It was therefore concluded that the 
therapy was cost effective.
 In terms of budget impact, the study considered 
the incremental cost of 1-year trastuzumab treatment 
as 2,000,000 to 4,000,000 yen. Then, by estimating 
the number of new breast cancer patients per year to 
be 40,000, of which 20% are HER2-positive, the total 
incremental cost was calculated as 16 to 32 billion yen, 
if all the HER2-positive patients were treated using 
trastuzumab.
 In summary, it is evident that economic evaluation 
will be needed to consider appropriate resource allocation 
under limited public funds for health care.
6. Values and Rewards of Innovative Cancer 
Drugs: Opportunities for R&D
 Woo Ick Jang (Handok) delivered a presentation 
from both medical oncology and industry perspectives. 
Cancer is increasingly becoming a chronic disease and 
targeted cancer drugs are being used more and more either 
as a single or combination therapy. Cancer treatment is 
therefore complex and expensive. Most targeted agents 
are equally expensive regardless of their value. There is a 
great deal of debate on cancer drug valuation mechanisms 
and a question that has recently been asked is whether the 
maximum tolerated price has been reached? The answer is 
very likely “yes,” but various action is being implemented 
on the part of oncologists and academia. 
Chronic myeloid leukemia (CML) experts have recently 
published a paper entitled “Price of drugs for CML, 
reflection of the unsustainable cancer drug prices: 
perspective of CML experts.” This study showed price 
disparities by country and region for the major drugs used 
to treat CML. 
 At the academic society level, the American Society 
of Clinical Oncology (ASCO) Guidance Statement on 
the Cost of Cancer Care was issued in 2009, which 
provides a concise overview of the economic issued facing 
stakeholders in the cancer community. The statement 
recommends patient-physician discussion about the costs 
of care. 
 The United States government implements comparative 
effectiveness research (CER) in order to compare health 
care services in a head-to-head manner. CER focuses 
on results obtained in the real world of typical patients 
and clinicians. The ultimate goal is to empower the 
government and private insurers to reduce healthcare costs 
by restricting access to expensive new medical tests and 
treatments. 
 Even in such an environment it is important for the 
pharmaceutical industry to listen to the opinions of key 
stakeholders, given the need to consider the payer’s 
perspective from the beginning of drug research and 
development.  
 There are a number of case studies available that 
demonstrate a new approach for cancer drug development 
and there may be opportunities for R&D in Asia. These 
include drug development focusing on Asia-prevalent 
cancers and reducing development costs by shortening 
drug development time by rapid patient enrollment, 
as well as risk sharing using government funding, and 
collaboration with Asian cooperative study groups. 
Currently not many first-in-class innovative products 
are produced in Asia and they are considered to be high-
risk. More precise biomarker-driven drug development 
targeting sub-populations could be expected to have 
higher efficacy and better safety and have longer treatment 
duration. Beside first-in-class drug development, some 
Asian pharmaceutical companies tried to develop fast 
follow-on products aiming already known cancer targets 
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with relatively small development cost by accelerating 
product development. These products were approved by 
local regulatory authorities by accepting relatively simple 
studydesign.
 The first case study is that of Icotinib, a new lung cancer 
drug in China. This oral EGFR TKI (TID) was approved 
in 2011 in China only. The product was developed by 
Zhejiang Beta Pharma and was partly supported by grants 
from the Chinese National Key Special Program for 
Innovative Drugs. Phase 3 trial was completed quickly 
by rapid patients enrolment and by using  PFS as primary 
efficacy endpoint.
 The second case study is that of Radotinib, a new 
CML drug in Korea. The drug was approved as second 
line treatment in 2012, which has overall good efficacy 
and safety. It was developed by Il-Yang Pharm and partly 
supported by the government. These two cancer drugs 
show the possibility for domestic company to develop new 
cancer drugs quickly and cheaply, eventually providing 
better cost-effectiveness drug to the patients.
In conclusion, many questions remain concerning the 
values and rewards of new targeted cancer drugs, and 
stakeholder voices and opinions are increasing on this 
issue. An alternative development approach is required 
in order to reduce the price of cancer drugs.
7. Anti-cancer Drugs: Innovation and 
Improvement of Access 
 Masafumi Nogimori (Astellas Pharma Inc.) spoke 
about some approaches from the pharmaceutical industry 
to improve innovation and access to drugs. In advanced 
countries, cancer has become the number one cause of 
death, but on a global basis the number one cause of 
death is derived from cardiovascular diseases, including 
ischemic heart failure and stroke. Cardiovascular, cancer, 
diabetes, and chronic respiratory diseases are collectively 
known as non-communicable diseases (NCDs). According 
to WHO, more than 60% of all 57 million deaths 
worldwide were derived from NCDs in 2008 and this 
proportion is expected to reach 76% in 2030. In addition, 
the proportion of NCD deaths under the age of 60 in low 
and middle income countries is more than twice that of 
high income countries. It can be seen that NCDs therefore 
need to be given serious consideration.
 Over the last decade there have been significant 
innovations in cancer diagnosis and treatments. These 
include anti-angiogenic drugs, appropriate diagnostic 
devices, and cancer vaccinations, which have led us to 
a new era of cancer treatment. However, there are still 
unmet medical needs. 
 The pharmaceutical industry has 1,500 new drug 
candidates in the pipeline to treat NCDs, more than half 
of which are anti-cancer drugs. Research and development 
in this area has tried to identify a suitable biomarker 
that can be used to diagnose and monitor the disease in 
large patient populations. Many companies are using 
imaging and computational technologies to address the 
underlying mechanisms of cancers. This has led to several 
biotherapeutic advances in treating cancer. In fact, some 
cancers may be managed as chronic diseases. However, 
cancer remains one of the world’s largest healthcare 
challenges, with an estimated 12 million deaths annually 
expected by 2030.
 Taking the example of typical molecular targeted drug 
clinical data for non-small cell lung cancer, Tarceva and 
Iressa are EGFR-tyrosine kinase inhibitors and have been 
shown to be more effective in patients with EGFR mutation. 
Their response rates are higher, and the progression free 
survival (PFS) time is found to be significantly longer 
compared with traditional chemotherapies. These new 
drugs give patients new efficient options to fight cancer, 
however, the targeted patient population is significantly 
smaller that for chemotherapies. 
 The average cost of developing one new medicine 
has increased dramatically in recent years. Bringing a 
medicine to market in the early 2000s cost approximately 
US$1.2 billion, compared to approximately US$140 
million in the mid-1970s. One reason for the higher cost 
of R&D is the increase in the pharmaceutical R&D failure 
rate. This is because the R&D focus has been shifting to 
more challenging and difficult diseases. During the last 
decade, clinical trial designs and procedures have become 
much more complex, demanding more staff time and 
effort, and discouraging patient enrollment and retention. 
Therefore clinical trials have become lengthy and more 
costly. Although molecular targeted drugs give patients 
important benefits such as increasing success rates and 
fewer side effects, they are also costly. We need to seek 
better ways to tackle this issue globally. 
 When we look at high unmet medical needs in 
oncology, a sustainable improvement of health care must 
be accomplished. When we have efficacious innovative 
drugs we must also consider how to deliver the drugs 
appropriately and utilize healthcare systems optimally, 
for example. 
 In order to achieve sustainable global healthcare 
improvement, multi-sectoral cooperation among all 
stakeholders is imperative. Government, industry, 
academia and civil society need to work together to make 
healthcare systems sustainable and to improve access 
to healthcare beyond drug price issues. For instance, 
process innovation for the drug development / approval 
from regulatory science could be considered globally via 
academia, government, and the industry dialogue. Multi-
sectoral innovative cooperation is essential in order to 
continue to create new medicines and diagnostics and to 
contribute to improved access to medicine and care. 
8. Discussion
 Hideyuki Akaza (RCAST) asked Norie Kawahara 
(Chair of the Asia Cancer Forum) to make comments 
on the presentations. Norie Kawahara noted that the 
presentations had been most impressive and that they had 
shown that the importance of cost effectiveness cannot 
be underestimated. Without innovation medical service 
cannot be improved and new innovation has been the 
outcome of cancer research to date. It is now imperative 
to consider the meaning of innovation in response to the 
social agenda.
 Tomoyuki Kitagawa (Japanese Foundation for Cancer 
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presentation by Masafumi Nogimori and his focus on 
multi-sectoral cooperation in order to respond to soaring 
medical costs. The hospital visit rate among the Japanese 
population is much higher than other developed nations 
and Japanese medical institutions are using expensive 
medicines  luxuariously. It is important to ensure that 
medicines and treatment are used to the best effect. In 
Japan it will be important to attempt to change the behavior 
of the public so that they act more reasonably with regard 
to doctor/hospital visits. One of the reasons behind soaring 
medical costs in Japan is the aging population. In the future 
it might be necessary to encourage voluntary efforts of 
extremely aged people  who refuse to get terminal life-
prolonging maneuvers and also sophisticated/expensive 
treatment with only marginal effect, in order to lessen 
the burden on national health systems and the younger 
generation.
 Kazuo Tajima (UICC-Asia Regional Office) noted 
that the UICC Session had started in 2011, and at the 
inaugural session discussions focused on how to reduce 
costs. Since then discussions have shifted towards the 
issue of cost effectiveness. One way of reducing cost and 
boosting cost effectiveness would be to simplify clinical 
trials. Quality of life is an important criterion to consider 
when appraising cost effectiveness. The UICC seeks to 
promote equitable cancer treatment in developing and 
developed countries; however, costs can be prohibitive. 
It is important to develop guidelines for cancer treatment 
that can be adapted to deal with the actual situation on the 
ground. 
 Brian Berry (University of Tokyo) noted that he had 
found the presentations most insightful and the criteria 
used for assessing cost effectiveness had been new to him 
and would likely be new to many people. He suggested 
that it would be useful to consider ways to educate people 
about the cost-effectiveness appraisal process in the future, 
as a way of enlightening the public. 
 Keishi Yoshida (University of Tokyo) noted that the 
presentations had inspired him to concentrate on the 
patients in front of him when he became a medical doctor 
in the future. He noted that he had found the explanations 
about cost-effectiveness analysis most enlightening. 
 Jae Kyung Roh (Yonsei University) invited comments 
and questions from the floor. 
 Hiroshi Maeda (Sojo University, Kumamoto) noted 
that the Japanese national health system is unsustainable 
in its current state. The issue of medical cost containment 
is currently also a major issue in the United States. New 
and costly drugs are covered by medical insurance in 
Japan and this leads to people not giving thought to the 
cost of the drugs they are prescribed. He urged that the 
Japanese government consider the establishment of an 
independent body, such as NICE, that would deal with 
cost-effectiveness analysis. 
 Hajime Inoue (MHLW) responded that the UK 
National Health Service and the Japanese healthcare 
system are different in several ways. The UK is entirely 
taxpayer funded, whereas the Japanese healthcare system 
is a combination of health insurance premiums, taxpayer 
funds and out-of-pocket expenses. With regard to out-
of-pocket expenses, in the case of the UK approximately 
10% of the population are members of additional private 
insurance schemes, allowing them access to drugs that 
NICE does not approve. The question is whether such 
a system would be viewed as being socially acceptable 
in Japan, where there is a strong focus on equality in 
healthcare. 
 Jasdeep Hayre (NICE) added a point of clarification 
about the implementation of guidance at NICE. It is the 
case that if NICE issues guidance on the use of a certain 
drug, every healthcare authority in the country has to 
make funding available for that drug normally within three 
months. However, clinical guidelines and other guidance 
produced by NICE is not legally binding. The UK has 
a unique healthcare system in that it is almost entirely 
taxpayer-funded. This is a part of the social values of the 
UK, where the focus is on healthcare being provided free 
of charge, but perhaps at the expense of a certain degree 
of patient choice.
 Sukyeong Kim (HIRA) noted that in Korea the 
public contribution is as big as 85% of the national 
health insurance funding, with only 15% coming from 
government. The rapid increase in expenditure is an issue 
that needs tackling urgently and international cooperation 
will be required. There are many efforts around the 
world being implemented to ensure cost effectiveness 
in the healthcare field and sharing and reviewing these 
experiences would be useful for all countries. The positive 
list system in Korea was introduced to ensure that only 
cost-effective drugs are prescribed. In the initial stage 
of the positive list system there were complaints from 
companies about the lack of data available. Increased 
data would help the public to understand about the 
effectiveness and cost of the drugs they are using. 
 Hideyuki Akaza (RCAST) suggested that it would be 
important to consider changing the way in which R&D of 
anti-cancer drugs is implemented and in so doing reduce 
associated costs. 
 Takashi Fukuda (National Institute of Public Health) 
agreed with Sukyeong Kim that further international 
cooperation on cost-effectiveness analysis would be very 
useful, but noted that global trials of pipeline drugs are 
already being implemented. 
 Eun-Cheol Park (Yonsei University) noted that to 
reduce the development costs of new anti-cancer drugs, 
we have two strategies. The first strategy as proposed 
by Woo Ick Jang,is government-driven anti-cancer drug 
development that the role of government is control tower 
in early phase of clinical trial and funding source. The 
second strategy as proposed by Masafumi Nogimori, is 
high and multi-disciplinary cooperation with public and 
private partnership.
 Jasdeep Hayre (NICE) noted that there is the additional 
cost of the Health Technology Assessment (HTA) process, 
which is quite expensive. There is an initiative underway 
in Europe to streamline the HTA process through 
international cooperation to create standardized models 
(EUnetHTA). In terms of the evidence base, instead of 
having many head-to-head trials, it is possible to use 
other statistical methods such as network meta-analysis, 
which can be used to calculate the incremental effect in 
the absence of comprehensive head to head evidence. 
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However, less expenditure in data collection, lower 
quantity or quality of evidence may increase uncertainty 
estimating the drug’s effectiveness making it difficult for 
decision makers to give strong guidance.
 Masafumi Nogimori (Astellas Pharma Inc.) noted that 
in order to streamline total development cost a unified 
worldwide development and approval system would be 
ideal. However, taking a programmatic line, a mutual 
approval system could also be another option. To combine 
the wisdom of people must be essential. 
 Woo Ick Jang (Handok) noted that he had already 
referred to two cases where development costs had been 
kept to a low level, in the cases of Icotinib and Radotinib. 
Only phase II data was required for approval for Radotinib 
approval. In Korea, there are two funding mechanisms for 
drug development funded by government, such as National 
OncoVenture, specialized for cancer development, and 
the Korea Drug Development Fund for all therapeutic 
areas. Review committee members comprise many 
people who have overseas experience and are able to 
bring their expertise to the process of developing and 
gaining approval for new drugs. We need to do active 
collaboration between industry, regulatory agencies and 
other stakeholders to develop more cost-effective drugs.
9. Closing Remarks
 Jae Kyung Roh (Yonsei University) thanked all the 
presenters for their valuable inputs and thanked the 
UICC-ARO for its support. He expressed his appreciation 
to Norie Kawahara for organizing the UICC session and 
closed the proceedings. 
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